
City Therapeutics files for IPO to fund RNAi drug trials targeting thrombosis
City Therapeutics is preparing for a U.S. IPO to raise funds for its RNAi therapeutic pipeline, including its lead candidate CITY-FXI aimed at treating thrombosis. The company has shown promising early Phase 1 results and benefits from strong partner...





